When does Mankind Pharma IPO subscription close?

Mankind Pharma IPO subscription closes on 2023-04-27.

MANKINDEQ / NSE, BSEListed

Mankind Pharma

Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products across a wide range of acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. The company offers over 36 brands such as Manforce, Moxikind-CV, Amlokind-AT, Prega News, and Gudcef, supported by one of the largest distribution networks of medical representatives in India, with over 80% of doctors prescribing its formulations. Ranked 4th in domestic sales in FY2022, Mankind Pharma has received numerous awards, including The Best of Bharat Awards 2022, National Awards for Manufacturing Competitiveness Silver Medal 2021, and recognition for Best Design in Healthcare and performance management excellence.

₹1,026 - ₹1,08016.12x sub

Listed Price₹1300.00

Listing Gain+20.37%

MANKINDEQ / NSE, BSEListed

Mankind Pharma IPO Subscription

Q: What is the live subscription status of Mankind Pharma IPO?

Mankind Pharma IPO has been subscribed 15.32x overall across Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII), and Retail Individual Investors.

Price Band₹1026 - ₹1080

Lot Size13 shares

Min Bid₹14,040

Subscription16.12x

Listed Market Snapshot

₹1300.00Listed price from market data

+20.37%listing gain

Issue Amount

₹4,326.36 Cr

Listed Price

₹1300.00

Current Price

₹2253.2

Registrar

KFin Technologies Limited

Subscription Status

16.12xTotal Demand

Updated 20 Oct 2026, 01:30 AM

QIB51.74x

🔥 Blockbuster Sizzling Demand!Offered: 76,11,181 sh

Nib4.00x

Popular / Warm DemandOffered: 57,08,386 sh

Hnis(10l +)5.26x

Popular / Warm DemandOffered: 38,05,591 sh

Hnis (2-10l)1.48x

Fully Subscribed (Safe)Offered: 19,02,795 sh

Retail0.97x

Steady / DevelopingOffered: 1,33,19,566 sh

Category	Offered (Shares)	Applied (Shares)	Times Subscribed
QIB	76,11,181	39,38,34,103	51.74x
Nib	57,08,386	2,28,22,761	4x
Hnis(10l +)	38,05,591	2,00,00,500	5.26x
Hnis (2-10l)	19,02,795	28,22,261	1.48x
Retail	1,33,19,566	1,28,56,038	0.97x

Category	Offered	Applied	Times
QIB	76,11,181	39,38,34,103	51.74x
Nib	57,08,386	2,28,22,761	4x
Hnis(10l +)	38,05,591	2,00,00,500	5.26x
Hnis (2-10l)	19,02,795	28,22,261	1.48x
Retail	1,33,19,566	1,28,56,038	0.97x

Segment Subscription Demand

Segment / Category	Demand (Shares)	Offered (Shares)	Times Sub.
QIB	42,534.08	822.01	51.74x
Retail	1,388.45	1,438.51	0.97x
Hnis 2+	304.8	205.5	1.48x
Hnis 10+	2,160.05	411	5.26x

Bidding status cross-verified with live IPO subscription numbers ↗BSE & NSE Bidding Portal Feed

About Mankind Pharma IPO Subscription Demand

Live subscription status and bidding analysis for Mankind Pharma (MANKIND) IPO. The issue is subscribed 16.12x overall across Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII/HNI), and Retail Individual Investors (RII). Check real-time grey market demand on our GMP Tracker or review full issue details, lot size, and price band on the IPO Details Page.

Mankind Pharma IPO Subscription

Subscription Status

Segment Subscription Demand

About Mankind Pharma IPO Subscription Demand

Frequently Asked Questions